Design and considerations of cardiovascular outcomes trials in type 2 diabetes
10.3760/cma.j.cn311282-20250120-00040
- VernacularTitle:2型糖尿病心血管结局试验的设计与思考
- Author:
Yingying LUO
1
;
Rui WANG
;
Linong JI
Author Information
1. 北京大学人民医院内分泌科，北京 100044
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus, type 2;
Cardiovascular outcomes;
Study design;
Active-controlled;
Tirzepatide
- From:
Chinese Journal of Endocrinology and Metabolism
2025;41(9):793-798
- CountryChina
- Language:Chinese
-
Abstract:
Recent large cardiovascular outcomes trials(CVOT) in patients with type 2 diabetes mellitus have demonstrated that several glucose-lowering agents provide cardiovascular benefits, advancing treatment concepts while also posing new ethical and clinical challenges for the design and conduct of future trials if traditional placebo-controlled designs are continued. In this context, conducting active-controlled CVOTs with optimized design strategies should be considered as a future research trend. This article reviews the design and clinical implications of CVOTs for glucose-lowering agents and explores potential directions for improvement, aiming to provide insights into optimized design strategies for future trials.
